Immunotherapy has moved to the forefront of modern oncologic treatment in the past few
decades. Various forms of immunotherapy currently are emerging, including oncolytic …

Malignant brain tumors constitute nearly one-third of cancer diagnoses in children and have
recently surpassed hematologic malignancies as the most lethal neoplasm in the pediatric …

Background JX-594 is a targeted oncolytic poxvirus designed to selectively replicate in and
destroy cancer cells with cell-cycle abnormalities and epidermal growth factor receptor …

Abstract Interleukin-12 (IL-12) has emerged as one of the most potent agents for anti-tumor
immunotherapy. However, potentially lethal toxicity associated with systemic administration …

Targeted oncolytic viruses and immunostimulatory therapeutics are being developed as
novel cancer treatment platforms. These approaches can be combined through the …

A major impediment to the successful application of gene therapy for the treatment of a
range of diseases is not a paucity of therapeutic genes, but the lack of an efficient non‐toxic …

Immune checkpoint inhibitors, including anti-programmed cell death 1 (PD-1) antibody,
provide improved clinical outcome in certain cancers. However, pancreatic ductal …

Targeted therapy of cancer using oncolytic viruses has generated much interest over the
past few years in the light of the limited efficacy and side effects of standard cancer …

Simple Summary Immunotherapy has revolutionized cancer treatment, as demonstrated by
the tremendous success of checkpoint inhibitors in different tumor types. Unfortunately, most …

Glioblastoma (GBM) is the most common primary malignant tumor in the brain, accounting
for 51.4% of all primary brain tumors. GBM has a highly immunosuppressive tumor …